Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
Haemophilia. 2009 Jul;15(4):843-52. doi: 10.1111/j.1365-2516.2008.01961.x. Epub 2009 Apr 7.
Patient-reported outcome (PRO) measures have been used to assess quality of life and health state preferences from the patient's perspective. However, they have not been fully utilized in haemophilia clinical practice and research. A series of meetings were convened to review and document the state of the art in PROs relevant to haemophilia. Experts developed a process for selection of measures and identified published measures of health-related quality of life (HRQoL) relevant to patients with haemophilia. These were synthesized and reviewed. Patient preference measures were also identified and reviewed. Although the majority of measures were developed for and validated in adults, several measures were identified for use in paediatric populations. This paper recommends an approach to the selection of PROs for application in haemophilia clinical research and practice and identifies several potential measures relevant for application in haemophilia clinical research and practice.
患者报告的结局(PRO)测量方法已被用于从患者角度评估生活质量和健康状况偏好。然而,它们在血友病的临床实践和研究中尚未得到充分利用。为此召开了一系列会议,以审查和记录与血友病相关的 PRO 的最新情况。专家们制定了一个选择措施的流程,并确定了与血友病患者相关的已发表的健康相关生活质量(HRQoL)测量方法。对这些方法进行了综合和审查。还确定并审查了患者偏好测量方法。尽管大多数测量方法是为成年人开发和验证的,但也确定了一些适用于儿科人群的测量方法。本文建议了一种在血友病临床研究和实践中应用 PRO 的选择方法,并确定了一些在血友病临床研究和实践中可能适用的潜在措施。